We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App





Beckman Coulter's SARS-CoV-2 IgG II Antibody Test Receives FDA Emergency Use Authorization

By LabMedica International staff writers
Posted on 25 Mar 2021
Print article
Illustration
Illustration
Beckman Coulter’s (Brea, CA, USA) Access SARS-CoV-2 IgG II antibody assay received US Emergency Use Authorization (EUA) from the US Food and Drug Administration.

The semi-quantitative assay measures a patient's level of antibodies in response to a previous SARS-CoV-2 infection and provides a qualitative and numerical result of antibodies in arbitrary units (AU). The Access SARS-CoV-2 IgG II assay measures IgG antibodies directed to the receptor-binding domain of the spike protein of the coronavirus. The test has a confirmed 100% negative percent agreement (specificity) and a 98.9% positive percent agreement (sensitivity) at >/= 15 days post symptom onset. The Access SARS-CoV-2 IgG II assay can be used in Random Access Mode (RAM) and seamlessly integrates into existing workflows without batch processing. The Access SARS-CoV-2 IgG II antibody assay is now available in the US and countries accepting the CE Mark. Results of the new test are delivered on Beckman Coulter's immunoassay analyzers, including the DxI 800 high-throughput analyzer, capable of processing up to 4,800 samples per day.

"Effective and high-quality diagnostic solutions are essential in the fight against COVID-19," said Shamiram R. Feinglass, MD, M.P.H, chief medical officer at Beckman Coulter. "Antibody assays like our Access SARS-CoV-2 IgG II test can help researchers quantitatively determine the levels of IgG antibodies and enable them to assess the relative changes of an individual's immune response to the SARS-CoV-2 virus over time. This information is essential because it helps continually inform therapeutics and vaccine development."

New
Gold Supplier
SARS-CoV-2 Rapid Test
Vivalytic SARS-CoV-2 Rapid 39 Minute Test
New
Multi-Well Sample Loader
AccuLoader
New
Silver Supplier
COVID-19 Ag Rapid Test
COVID-19 Ag Rapid Test Kit
New
Wastewater SARS-CoV-2 RT-qPCR Kit
SARS-CoV-2 RT-qPCR Kit for Wastewater

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Randox Discovery Diagnostic Analyzer Wins 2021 Red Dot Award for High Design Quality (Photo courtesy of Randox Laboratories)

Randox Discovery Diagnostic Analyzer Wins 2021 Red Dot Award for High Design Quality

Randox Laboratories’ (Crumlin, UK) Discovery, a diagnostic analyzer which can consolidate molecular and immunoassay testing on one compact benchtop platform, has received the 2021 Red Dot Award for High... Read more

Industry

view channel
Image: Eppendorf Centrifuge 5910 Ri (Photo courtesy of Eppendorf AG)

Eppendorf Introduces Multipurpose Centrifuge 5910 Ri to Accelerate Results

Eppendorf AG (Hamburg, Germany) has introduced a new centrifuge designed to increase efficiency in the laboratory, Centrifuge 5910 Ri, a successor to the company’s popular Centrifuge 5910 R.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.